FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:908-914 March 25, 1999 Number 12 Next

	Full Text PDF Editorial by Brennan, M. F. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Curative resection is the treatment of choice for gastric cancer, but it is unclear whether this operation should include an extended (D2) lymph-node dissection, as recommended by the Japanese medical community, or a limited (D1) dissection. We conducted a randomized trial in 80 Dutch hospitals in which we compared D1 with D2 lymph-node dissection for gastric cancer in terms of morbidity, postoperative mortality, long-term survival, and cumulative risk of relapse after surgery.

Methods Between August 1989 and July 1993, a total of 996 patients entered the study. Of these patients, 711 (380 in the D1 group and 331 in the D2 group) underwent the randomly assigned treatment with curative intent, and 285 received palliative treatment. The procedures for quality control included instruction and supervision in the operating room and monitoring of the pathological results.

Results Patients in the D2 group had a significantly higher rate of complications than did those in the D1 group (43 percent vs. 25 percent, P<0.001), more postoperative deaths (10 percent vs. 4 percent, P= 0.004), and longer hospital stays (median, 16 vs. 14 days; P<0.001). Five-year survival rates were similar in the two groups: 45 percent for the D1 group and 47 percent for the D2 group (95 percent confidence interval for the difference, –9.6 percent to +5.6 percent). The patients who had R0 resections (i.e., who had no microscopical evidence of remaining disease), excluding those who died postoperatively, had cumulative risks of relapse at five years of 43 percent with D1 dissection and 37 percent with D2 dissection (95 percent confidence interval for the difference, –2.4 percent to +14.4 percent).

Conclusions Our results in Dutch patients do not support the routine use of D2 lymph-node dissection in patients with gastric cancer.

Source Information

From the Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands (J.J.B., C.J.H.V.), the Department of Medical Statistics, Leiden University, Leiden, the Netherlands (J.H.), and the National Cancer Center Hospital, Tokyo, Japan (M.S.). Other authors were K. Welvaart and I. Songun (Leiden University Medical Center); S. Meyer (University Hospital Amsterdam Vrije University); J.T.M. Plukker (University Hospital Groningen); P. Van Elk (Geertruiden Hospital Deventer); H. Obertop, D.J. Gouma, J.J.B. van Lanschot, and C.W. Taat (Amsterdam Academic Medical Center); P.W. de Graaf (Reinier de Graaf Hospital Delft); M.F. von Meyenfeldt (University Hospital Maastricht); and H. Tilanus (University Hospital Dijkzigt Rotterdam) — all in the Netherlands.

Address reprint requests to Prof. van de Velde at the Department of Surgery, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, the Netherlands, or at velde{at}surgery.azl.nl.

Full Text of this Article

Related Letters:

Surgery for Gastric Cancer
Pacelli F., Sgadari A., Doglietto G.B., Bonenkamp J.J., Sasako M., van de Velde C.
Extract | Full Text  
N Engl J Med 1999; 341:538-539, Aug 12, 1999. Correspondence

This article has been cited by other articles:

• Wilkinson, N. W., Howe, J., Gay, G., Patel-Parekh, L., Scott-Conner, C., Donohue, J. (2008). Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care Evaluation. Ann. Surg. Oncol. 15: 1644-1650 [Abstract] [Full Text]  
• Milne, A N A, Carvalho, R, Jansen, M, Kranenbarg, E K, van de Velde, C J H, Morsink, F M, Musler, A R, Weterman, M A J, Offerhaus, G J A (2008). Cyclin E low molecular weight isoforms occur commonly in early-onset gastric cancer and independently predict survival. J. Clin. Pathol. 61: 311-316 [Abstract] [Full Text]  
• Pritchard, S A (2008). Best practice in macroscopic examination of gastric resections. J. Clin. Pathol. 61: 172-178 [Abstract] [Full Text]  
• Izzo, J. G., Ajani, J. A. (2007). Thinking In and Out of the Box When It Comes to Gastric Cancer and Cyclooxygenase-2. JCO 25: 4865-4867 [Full Text]  
• de Maat, M. F.G., van de Velde, C. J.H., Umetani, N., de Heer, P., Putter, H., van Hoesel, A. Q., Meijer, G. A., van Grieken, N. C., Kuppen, P. J.K., Bilchik, A. J., Tollenaar, R. A.E.M., Hoon, D. S.B. (2007). Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. JCO 25: 4887-4894 [Abstract] [Full Text]  
• Lee, J. H., Kim, Y.-W., Ryu, K. W., Lee, J. R., Kim, C. G., Choi, I. J., Kook, M. C., Nam, B.-H., Bae, J.-M. (2007). A Phase-II Clinical Trial of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Gastric Cancer Patients. Ann. Surg. Oncol. 14: 3148-3153 [Abstract] [Full Text]  
• Iddings, D. M., Bilchik, A. (2007). Gastric carcinoma: applying the sentinel node paradigm to improve the understanding of metastatic patterns and the possible role of selective lymphadenectomy.. Ann. Surg. Oncol. 14: 2432-2434 [Full Text]  
• Guo, E., Chen, L., Xie, Q., Chen, J., Tang, Z., Wu, Y. (2007). Serum HDL-C as a Potential Biomarker for Nodal Stages in Gastric Cancer. Ann. Surg. Oncol. 14: 2528-2534 [Abstract] [Full Text]  
• Pedrazzani, C., de Manzoni, G., Marrelli, D., Giacopuzzi, S., Corso, G., Minicozzi, A. M., Rampone, B., Roviello, F. (2007). Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J. Thorac. Cardiovasc. Surg. 134: 378-385 [Abstract] [Full Text]  
• De Vita, F, Giuliani, F, Orditura, M, Maiello, E, Galizia, G, Di Martino, N, Montemurro, F, Carteni, G, Manzione, L, Romito, S, Gebbia, V, Ciardiello, F, Catalano, G, Colucci, G (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 18: 1354-1358 [Abstract] [Full Text]  
• Lee, J. H., Paik, Y. H., Lee, J. S., Ryu, K. W., Kim, C. G., Park, S. R., Kim, Y. W., Kook, M. C., Nam, B.-h., Bae, J.-M. (2007). Abdominal Shape of Gastric Cancer Patients Influences Short-Term Surgical Outcomes. Ann. Surg. Oncol. 14: 1288-1294 [Abstract] [Full Text]  
• Barbour, A. P., Rizk, N. P., Gonen, M., Tang, L., Bains, M. S., Rusch, V. W., Coit, D. G., Brennan, M. F. (2007). Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. Ann. Surg. Oncol. 14: 306-316 [Abstract] [Full Text]  
• Schwarz, R. E., Smith, D. D. (2007). Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann. Surg. Oncol. 14: 317-328 [Abstract] [Full Text]  
• Nishikawa, T., Maetani, S. (2007). Evaluation of Intensive Adjuvant Chemotherapy in Gastric Cancer Using Life Expectancy Compared with Log-Rank Test as a Measure of Survival Benefit. Ann. Surg. Oncol. 14: 348-354 [Abstract] [Full Text]  
• Gee, D. W., Rattner, D. W. (2007). Management of Gastroesophageal Tumors. The Oncologist 12: 175-185 [Abstract] [Full Text]  
• Marrelli, D., Pedrazzani, C., Neri, A., Corso, G., DeStefano, A., Pinto, E., Roviello, F. (2007). Complications after Extended (D2) and Superextended (D3) Lymphadenectomy for Gastric Cancer: Analysis of Potential Risk Factors. Ann. Surg. Oncol. 14: 25-33 [Abstract] [Full Text]  
• Lee, J. H., Ryu, K. W., Lee, J.-H., Park, S. R., Kim, C. G., Kook, M. C., Nam, B.-H., Kim, Y.-W., Bae, J.-M. (2006). Learning Curve for Total Gastrectomy with D2 Lymph Node Dissection: Cumulative Sum Analysis for Qualified Surgery. Ann. Surg. Oncol. 13: 1175-1181 [Abstract] [Full Text]  
• Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J.H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., Smith, D. B., Langley, R. E., Verma, M., Weeden, S., Chua, Y. J., the MAGIC Trial Participants, (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.. NEJM 355: 11-20 [Abstract] [Full Text]  
• Costa, M. L. V., de Cassia Braga Ribeiro, K., Machado, M. A. C., Costa, A. C. L. V., Montagnini, A. L. (2006). Prognostic Score in Gastric Cancer: The Importance of a Conjoint Analysis of Clinical, Pathologic, and Therapeutic Factors. Ann. Surg. Oncol. 13: 843-850 [Abstract] [Full Text]  
• Ohtsu, A., Yoshida, S., Saijo, N. (2006). Disparities in Gastric Cancer Chemotherapy Between the East and West. JCO 24: 2188-2196 [Abstract] [Full Text]  
• Black, E., Niamat, J., Boddu, S., Martin-Ucar, A., Duffy, J. P., Morgan, W. E., Beggs, F. D. (2006). Unplanned splenectomy during oesophagectomy does not affect survival. Eur. J. Cardiothorac. Surg. 29: 244-247 [Abstract] [Full Text]  
• Nitti, D., Wils, J., Dos Santos, J. G., Fountzilas, G., Conte, P. F., Sava, C., Tres, A., Coombes, R. C., Crivellari, D., Marchet, A., Sanchez, E., Bliss, J. M., Homewood, J., Couvreur, M. L., Hall, E., Baron, B., Woods, E., Emson, M., Van Cutsem, E., Lise, M. (2006). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 17: 262-269 [Abstract] [Full Text]  
• Baxter, N. N., Tuttle, T. M. (2005). Inadequacy of Lymph Node Staging in Gastric Cancer Patients: A Population-Based Study. Ann. Surg. Oncol. 12: 981-987 [Abstract] [Full Text]  
• Smith, D. D., Schwarz, R. R., Schwarz, R. E. (2005). Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database. JCO 23: 7114-7124 [Abstract] [Full Text]  
• Yun, M., Lim, J. S., Noh, S. H., Hyung, W. J., Cheong, J. H., Bong, J. K., Cho, A., Lee, J. D. (2005). Lymph Node Staging of Gastric Cancer Using 18F-FDG PET: A Comparison Study with CT. JNM 46: 1582-1588 [Abstract] [Full Text]  
• Kollmannsberger, C., Budach, W., Stahl, M., Schleucher, N., Hehr, T., Wilke, H., Schleicher, J., Vanhoefer, U., Jehle, E. C., Oechsle, K., Trarbach, T., Boehlke, I., Kanz, L., Hartmann, J. T., Bokemeyer, C. (2005). Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol 16: 1326-1333 [Abstract] [Full Text]  
• Ajani, J.A., Mansfield, P.F., Crane, C.H., Wu, T.T., Lunagomez, S., Lynch, P.M., Janjan, N., Feig, B., Faust, J., Yao, J.C., Nivers, R., Morris, J., Pisters, P.W. (2005). Paclitaxel-Based Chemoradiotherapy in Localized Gastric Carcinoma: Degree of Pathologic Response and Not Clinical Parameters Dictated Patient Outcome. JCO 23: 1237-1244 [Abstract] [Full Text]  
• Lee, W.-J., Kappas, A. M., Fatouros, M., Roukos, D. H. (2005). It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer. Ann. Surg. Oncol. 12: 194-196 [Full Text]  
• Kappas, A. M., Fatouros, M., Roukos, D. H. (2004). Editorial: Is it Time to Change Surgical Strategy for Gastric Cancer in the United States?. Ann. Surg. Oncol. 11: 727-730 [Full Text]  
• Ajani, J.A., Mansfield, P.F., Janjan, N., Morris, J., Pisters, P.W., Lynch, P.M., Feig, B., Myerson, R., Nivers, R., Cohen, D.S., Gunderson, L.L. (2004). Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma. JCO 22: 2774-2780 [Abstract] [Full Text]  
• Birkmeyer, J. D. (2004). Understanding Surgeon Performance and Improving Patient Outcomes. JCO 22: 2765-2766 [Full Text]  
• Mansfield, P. F. (2004). Lymphadenectomy for Gastric Cancer. JCO 22: 2759-2761 [Full Text]  
• Weitz, J., Jaques, D. P., Brennan, M., Karpeh, M. (2004). Association of Splenectomy With Postoperative Complications in Patients With Proximal Gastric and Gastroesophageal Junction Cancer. Ann. Surg. Oncol. 11: 682-689 [Abstract] [Full Text]  
• Hartgrink, H.H., van de Velde, C.J.H., Putter, H., Bonenkamp, J.J., Klein Kranenbarg, E., Songun, I., Welvaart, K., van Krieken, J.H.J.M., Meijer, S., Plukker, J.T.M., van Elk, P.J., Obertop, H., Gouma, D.J., van Lanschot, J.J.B., Taat, C.W., de Graaf, P.W., von Meyenfeldt, M.F., Tilanus, H., Sasako, M. (2004). Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial. JCO 22: 2069-2077 [Abstract] [Full Text]  
• Dicken, B.J., Saunders, L.D., Jhangri, G.S., de Gara, C., Cass, C., Andrews, S., Hamilton, S.M. (2004). Gastric Cancer: Establishing Predictors of Biologic Behavior with Use of Population-Based Data. Ann. Surg. Oncol. 11: 629-635 [Abstract] [Full Text]  
• Bollschweiler, E. H., Monig, S. P., Hensler, K., Baldus, S. E., Maruyama, K., Holscher, A. H. (2004). Artificial Neural Network for Prediction of Lymph Node Metastases in Gastric Cancer: A Phase II Diagnostic Study. Ann. Surg. Oncol. 11: 506-511 [Abstract] [Full Text]  
• Ajani, J. A. (2004). Operate on My Stomach Cancer? Oh, No--Not You, or Not Yet!. JCO 22: 1763-1764 [Full Text]  
• van Beek, J., zur Hausen, A., Klein Kranenbarg, E., van de Velde, C. J.H., Middeldorp, J. M., van den Brule, A. J.C., Meijer, C. J.L.M., Bloemena, E. (2004). EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node Involvement. JCO 22: 664-670 [Abstract] [Full Text]  
• Roukos, D. H. (2004). Early-Stage Gastric Cancer: A Highly Treatable Disease. Ann. Surg. Oncol. 11: 127-129 [Full Text]  
• Weitz, J., D'Angelica, M., Gonen, M., Klimstra, D., Coit, D. G., Brennan, M. F., Karpeh, M. S. (2003). Interaction of Splenectomy and Perioperative Blood Transfusions on Prognosis of Patients With Proximal Gastric and Gastroesophageal Junction Cancer. JCO 21: 4597-4603 [Abstract] [Full Text]  
• Peeters, K.C.M.J., van de Velde, C.J.H. (2003). Improving Treatment Outcome for Gastric Cancer: The Role of Surgery and Adjuvant Therapy. JCO 21: 272s-273 [Full Text]  
• Sasako, M. (2003). Principles of Surgical Treatment for Curable Gastric Cancer. JCO 21: 274s-275 [Full Text]  
• Nitti, D., Marchet, A., Olivieri, M., Ambrosi, A., Mencarelli, R., Belluco, C., Lise, M. (2003). Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience. Ann. Surg. Oncol. 10: 1077-1085 [Abstract] [Full Text]  
• Shimoyama, S., Mafune, K.-i., Kaminishi, M. (2003). Indications for a Pylorus-Preserving Gastrectomy for Gastric Cancer With Proper Muscle Invasion. Arch Surg 138: 1235-1239 [Abstract] [Full Text]  
• Park, S. H., Kim, D. Y., Heo, J. S., Lim, D. H., Park, C. K., Lee, K. W., Choi, S. H., Sohn, T. S., Kim, S., Noh, J. H., Kim, Y. I., Park, J. O., Kim, K., Kim, W. S., Jung, C. W., Im, Y. H., Lee, M. H., Park, K., Park, C. H., Kang, W. K. (2003). Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 14: 1373-1377 [Abstract] [Full Text]  
• van de Velde, C. J.H., Peeters, K. C.M.J. (2003). The Gastric Cancer Treatment Controversy. JCO 21: 2234-2236 [Full Text]  
• Gill, S., Shah, A., Le, N., Cook, E. F., Yoshida, E. M. (2003). Asian Ethnicity-Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center. JCO 21: 2070-2076 [Abstract] [Full Text]  
• Gretschel, S., Christoph, F., Bembenek, A., Estevez-Schwarz, L., Schneider, U., Schlag, P. M. (2003). Body Mass Index Does Not Affect Systematic D2 Lymph Node Dissection and Postoperative Morbidity in Gastric Cancer Patients. Ann. Surg. Oncol. 10: 363-368 [Abstract] [Full Text]  
• Douglass, H. O. (2003). Gastric Cancer: D2 All Over Again. Ann. Surg. Oncol. 10: 206-207 [Full Text]  
• Sierra, A., Regueira, F. M., Hernandez-Lizoain, J. L., Pardo, F., Martinez-Gonzalez, M. A., A.-Cienfuegos, J. (2003). Role of the Extended Lymphadenectomy in Gastric Cancer Surgery: Experience in a Single Institution. Ann. Surg. Oncol. 10: 219-226 [Abstract] [Full Text]  
• Roukos, D. H., Briasoulis, E., Michos, K. M., Elisaf, M., Agnantis, N. J., Kappas, A. M. (2003). Breast and Gastric Cancer: Comparing What We Learn. Ann. Surg. Oncol. 10: 92-94 [Full Text]  
• Kitajima, M., Kitagawa, Y. (2002). Surgical Treatment of Esophageal Cancer -- The Advent of the Era of Individualization. NEJM 347: 1705-1709 [Full Text]  
• Kappas, A. M., Roukos, D. H. (2002). Quality of Surgery Determinant for the Outcome of Patient With Gastric Cancer. Ann. Surg. Oncol. 9: 828-830 [Full Text]  
• Roviello, F., Marrelli, D., Morgagni, P., de Manzoni, G., Di Leo, A., Vindigni, C., Saragoni, L., Tomezzoli, A., Kurihara, H. (2002). Survival Benefit of Extended D2 Lymphadenectomy in Gastric Cancer With Involvement of Second Level Lymph Nodes: A Longitudinal Multicenter Study. Ann. Surg. Oncol. 9: 894-900 [Abstract] [Full Text]  
• Bando, E., Yonemura, Y., Taniguchi, K., Fushida, S., Fujimura, T., Miwa, K. (2002). Outcome of Ratio of Lymph Node Metastasis in Gastric Carcinoma. Ann. Surg. Oncol. 9: 775-784 [Abstract] [Full Text]  
• Sano, T., Yamamoto, S., Sasako, M. (2002). Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: Japan Clinical Oncology Group Study JCOG 0110-MF. Jpn J Clin Oncol 32: 363-364 [Abstract] [Full Text]  
• McCulloch, P., Taylor, I., Sasako, M., Lovett, B., Griffin, D. (2002). Randomised trials in surgery: problems and possible solutions. BMJ 324: 1448-1451 [Full Text]  
• Allum, W H, Griffin, S M, Watson, A, Colin-Jones, D (2002). Guidelines for the management of oesophageal and gastric cancer. Gut 50 : v1-v23 [Full Text]  
• Schwarz, R. E., Zagala-Nevarez, K. (2002). Recurrence Patterns After Radical Gastrectomy for Gastric Cancer: Prognostic Factors and Implications for Postoperative Adjuvant Therapy. Ann. Surg. Oncol. 9: 394-400 [Abstract] [Full Text]  
• Yoshikawa, T., Tsuburaya, A., Kobayashi, O., Sairenji, M., Motohashi, H., Noguchi, Y. (2002). Is D2 Lymph Node Dissection Necessary for Early Gastric Cancer?. Ann. Surg. Oncol. 9: 401-405 [Abstract] [Full Text]  
• Roukos, D. H. (2002). Adjuvant Chemoradiotherapy in Gastric Cancer: Wave Goodbye to Extensive Surgery?. Ann. Surg. Oncol. 9: 220-221 [Full Text]  
• Hundahl, S. A., Macdonald, J. S., Benedetti, J., Fitzsimmons, T. (2002). Surgical Treatment Variation in a Prospective, Randomized Trial of Chemoradiotherapy in Gastric Cancer: The Effect of Undertreatment. Ann. Surg. Oncol. 9: 278-286 [Abstract] [Full Text]  
• Bajetta, E., Buzzoni, R., Mariani, L., Beretta, E., Bozzetti, F., Bordogna, G., Aitini, E., Fava, S., Schieppati, G., Pinotti, G., Visini, M., Ianniello, G., Di Bartolomeo, M. (2002). Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 13: 299-307 [Abstract] [Full Text]  
• Shoup, M., Brennan, M. F., McWhite, K., Leung, D. H. Y., Klimstra, D., Conlon, K. C. (2002). The Value of Splenic Preservation With Distal Pancreatectomy. Arch Surg 137: 164-168 [Abstract] [Full Text]  
• Abraham, I., Dhar, P., Praseedom, R. K., Atkins, C. D., Berney, C. R., Merrett, N. D., Macdonald, J. S., Benedetti, J., Hundahl, S. A. (2002). Adjuvant Chemoradiotherapy for Gastric Cancer. NEJM 346: 210-211 [Full Text]  
• Inoue, K., Nakane, Y., Iiyama, H., Sato, M., Kanbara, T., Nakai, K., Okumura, S., Yamamichi, K., Hioki, K. (2002). The Superiority of Ratio-Based Lymph Node Staging in Gastric Carcinoma. Ann. Surg. Oncol. 9: 27-34 [Abstract] [Full Text]  
• Macdonald, J. S., Smalley, S. R., Benedetti, J., Hundahl, S. A., Estes, N. C., Stemmermann, G. N., Haller, D. G., Ajani, J. A., Gunderson, L. L., Jessup, J. M., Martenson, J. A. (2001). Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. NEJM 345: 725-730 [Abstract] [Full Text]  
• Roukos, D. H., Kappas, A. M. (2001). Limitations in Controlling Risk for Recurrence After Curative Surgery for Advanced Gastric Cancer Are Now Well-Explained by Molecular-Based Mechanisms. Ann. Surg. Oncol. 8: 620-621 [Full Text]  
• (2001). East is East and West was West: Closing the Gap in the Delivery of Gastric Cancer Surgery. Jpn J Clin Oncol 31: 469-470 [Full Text]  
• Ota, D. M. (2001). A Pilot Study of Preoperative Chemoradiation for Gastric Cancer. Ann. Surg. Oncol. 8: 482-483 [Full Text]  
• Lee, K. Y., Noh, S. H., Hyung, W. J., Lee, J. H., Lah, K. H., Choi, S. H., Min, J. S. (2001). Impact of Splenectomy for Lymph Node Dissection on Long-Term Surgical Outcome in Gastric Cancer. Ann. Surg. Oncol. 8: 402-406 [Abstract] [Full Text]  
• Schwarz, R. E., Kelsen, D. P. (2001). Postoperative Adjuvant Chemoradiation Therapy for Patients With Resected Gastric Cancer: Intergroup 116. JCO 19: 1879-1880 [Full Text]  
• Melville, A, Eastwood, A, Morris, E, Forman, D (2001). Management of upper gastrointestinal cancers. Qual Saf Health Care 10: 57-64 [Full Text]  
• Kelsen, D. P. (2000). Postoperative Adjuvant Chemoradiation Therapy for Patients With Resected Gastric Cancer: Intergroup 116. JCO 18: 32s-34 [Full Text]  
• Davis, P. A. (2000). The Management of Patients with Gastric Cancer: Can West Meet East?. Jpn J Clin Oncol 30: 463- [Full Text]  
• Cady, B. (2000). Sentinel Lymph Node Procedure in Squamous Cell Carcinoma of the Vulva. JCO 18: 2795-2797 [Full Text]  
• Doglietto, G. B., Pacelli, F., Caprino, P., Bossola, M., Stasi, C. D. (2000). Pancreas-Preserving Total Gastrectomy for Gastric Cancer. Arch Surg 135: 89-92 [Abstract] [Full Text]  
• Pacelli, F., Sgadari, A., Doglietto, G.B., Bonenkamp, J.J., Sasako, M., van de Velde, C. (1999). Surgery for Gastric Cancer. NEJM 341: 538-539 [Full Text]  
• Brennan, M. F. (1999). Lymph-Node Dissection for Gastric Cancer. NEJM 340: 956-958 [Full Text]